{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-015596","form_type":"8-K","ticker":"RNLXY","cik":"0001811115","company_name":"Renalytix plc","filed_at":"2024-02-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.629736+00:00","generated_at":"2026-06-06T01:26:29.757070+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Renalytix Q2 FY2024 revenue $0.7M, net loss $8.5M; CMS sets $950/test","bullets":["Revenue $0.7M from KidneyIntelX (down from $1.0M YoY); no pharma services revenue.","Net loss improved to $8.5M from $10.4M YoY; cash & equivalents $5.6M at Dec 31, 2023.","CMS finalized $950/test lab fee for kidneyintelX.dkd; NGS resumed claim payment.","Targeting ~33% lower cash burn in Q3 FY2024 vs Q2; annualized burn under $23M.","Published real-world evidence: 61% increase in kidney protective drug prescriptions after testing."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-015596","json":"https://secwatch.observer/filing/0000950170-24-015596.json","markdown":"https://secwatch.observer/filing/0000950170-24-015596.md","text":"https://secwatch.observer/filing/0000950170-24-015596.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1811115/000095017024015596/0000950170-24-015596-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1811115/000095017024015596/rnlx-20240215.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T01:26:29.757070+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5e8e70ef46a1b51ea8544bd1eb266dbf34dc887f","claim":"Renalytix plc reported second quarter ended December 31, 2023 results: revenue $0.7 million, net income Net loss was $8.5 million.","evidence_excerpt":"During the three months ended December 31, 2023, we recognized $0.7 million of revenue related to sales of KidneyIntelX.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1811115/000095017024015596/0000950170-24-015596-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"second quarter ended December 31, 2023"},{"label":"Revenue","value":"$0.7 million"},{"label":"Net income","value":"Net loss was $8.5 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}